Five Lupus Patients in England Achieve Remission After NHS Gene Therapy Trial

1-Minute Brief

This development highlights a potential new approach for treating chronic autoimmune diseases using genetically modified immune cells.

Key Facts

• Five lupus patients in England have gone into remission following a trial of genetically modified cell therapy.
• The therapy involves modifying a patient’s T-cells to help the immune system target problem cells.
• Doctors describe the treatment as a medical breakthrough that could offer a cure for lupus.
• The therapy used is called CAR (chimeric antigen receptor) T-cell therapy.
• The NHS oversaw the trial, which used patients’ own cells for genetic modification.

What Happened

A group of five lupus patients in England entered remission after receiving a therapy that genetically modifies their own T-cells, as part of an NHS trial.

Why It Matters

The results suggest that gene-modified immune cell therapies could provide new treatment options for chronic autoimmune diseases like lupus, which currently have limited curative therapies.

What's Next

Further studies and trials may be conducted to assess the safety, effectiveness, and broader applicability of this therapy for lupus and potentially other autoimmune conditions.